IAVI is a global not-for-profit organization working to accelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996, IAVI researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field. IAVI also works to ensure that AIDS vaccines are a global priority and that a future vaccine will be accessible to all who need it. IAVI is registered as a foundation (Stichting IAVI) under Dutch law and the Amsterdam office oversees its extensive European program.

“In Europe, IAVI has partnered with academic institutions, biotechnology firms, and pharmaceutical companies to implement five vaccine development projects.”

Research and Development (R&D)

In Europe, IAVI has partnered with academic institutions, biotechnology firms, and pharmaceutical companies to implement five vaccine development projects: Oxford University (UK), Bioption (Sweden), FIT Biotech (Finland), Crucell (The Netherlands), and GSK Biologicals (Belgium). IAVI has also established vaccine manufacturing agreements with Berna (Switzerland), IDT (Germany), Cobra (UK), and Transgene (France). Early-phase clinical trials of AIDS vaccine candidates were conducted by IAVI in the United Kingdom, Belgium, Germany, and Switzerland.

Laura Seamons, Andy Cooper, Tony Tarraguna, and Peter Hayes using BD flow cytometer at the Core Laboratory in London

IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
**IAVI Core Lab at Imperial College London:** The IAVI Human Core Immunology Laboratory (the Core Lab) plays a pivotal role in the evaluation of IAVI-sponsored AIDS vaccine candidates. It serves as IAVI’s main laboratory, providing comprehensive ongoing training to field laboratory and clinical staff involved in IAVI-sponsored trials.

**Crucell:** IAVI entered into an agreement with Dutch biotechnology company Crucell to develop an AIDS vaccine based on Crucell’s AdVac adenovirus vector technology and obtained the rights from Crucell to use a cell line for these vectors. IAVI intends to bring a candidate vaccine based on this technology into human clinical trials in 2007.

**GSK Biologicals:** In June 2005, IAVI and GSK Biologicals signed a collaborative agreement to construct and evaluate the potential of chimpanzee adenovirus vectors as human vaccines for HIV. Under this collaboration, two vectors are being constructed with identical HIV genes to those used in the Crucell program.

**EuroVacc Foundation:** EuroVacc and IAVI signed a memorandum of understanding in 2004, establishing a framework for future collaboration in developing and evaluating HIV vaccines for the European Union (EU) and the rest of the world.

**Neutralizing Antibody Consortium:** IAVI is working closely with senior scientists to tackle key challenges in AIDS vaccine research. In Europe, scientists from the University of Oxford (UK) and the Centre d’Immunologie de Marseille-Luminy (France) participate in the Neutralizing Antibody Consortium. This consortium aims to design vaccine candidates that elicit broadly neutralizing antibodies, which may be a critical component of an effective vaccine.

**Mobilizing Community, Political, and Private Sector Support for AIDS Vaccine Research**

To gain support from governments and other relevant stakeholders for AIDS vaccine research, IAVI collaborates with governments, the EU Presidencies, the European Commission, parliamentarians, policy makers, the media, scientific communities, and European NGOs and related networks.

IAVI has established well-developed policy and advocacy networks in Europe through partnership agreements with national AIDS NGOs, including: AIDES (France), AIDS Fonds (Netherlands), AIDS Fondet (Denmark), Deutsche AIDS Stiftung (Germany), Finnish AIDS Council (Finland), gTt (Spain), National AIDS Trust (UK), Noah’s Ark-Red Cross Foundation (Sweden), HivNorge (Norway), and SENSOA (Belgium). IAVI’s and partner organizations’ efforts cover a wide spectrum of activities such as advocacy, policy development, fundraising, and community involvement in trials.

Working with the governments of Ireland, The Netherlands, and the United Kingdom during their consecutive EU Presidencies has resulted in increased attention for new prevention technologies in key policy initiatives and documents, including the Way Forward paper (Dublin 2004), the Vilnius Declaration on Measures to Strengthen Responses to HIV/AIDS in the European Union and in Neighboring Countries (September 2004), and the inclusion of AIDS vaccines in the Priority Medicines for the World report (November 2004).

IAVI also works with several Directorate Generals of the European Commission (EC). The organization played an active role in the consultation process for the European Programme for Action to confront
IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.

HIV/AIDS, Malaria, and Tuberculosis through External Action (2007-2011). The new Programme for Action (PfA) includes a recommendation for strong EU and EC support for public-private partnerships and global initiatives working on priority tools such as AIDS vaccines. IAVI is also involved in the consultation leading to the EU’s Seventh Framework Programme for R&D 2007-2013 (FP7), calling for support for translational research in infectious diseases to address the global threats of AIDS, malaria, and tuberculosis.

IAVI works with parliamentarians on various projects and initiatives. IAVI contributed to the expansion of the existing European Parliament Working Group on Population, Sustainable Development, and Reproductive Health (EPWG), which now includes representation from the new member states and a stronger HIV/AIDS commitment. IAVI provided input into the European Parliament’s Development Committee for its Report on Neglected Diseases in Developing Countries, which now highlights public-private partnerships such as IAVI as key to innovation and capacity building.

IAVI is also one of the founding members of the informal EU HIV/AIDS group of NGOs that holds regular meetings and initiates broader coalitions for HIV/AIDS policy, as well as a member of influential Brussels-based think tanks, such as the European Policy Centre.

**IAVI’s Donors**

IAVI’s financial and in-kind supporters include the Alfred P. Sloan Foundation, the Bill & Melinda Gates Foundation, The New York Community Trust, The Rockefeller Foundation, and The Starr Foundation; the Governments of the Basque Country, Canada, Denmark, European Union, Ireland, The Netherlands, Norway, Sweden, United Kingdom, and the United States; multilateral organizations such as The World Bank; corporate donors including BD (Becton, Dickinson & Co.), Continental Airlines, DHL, Merck & Co. Inc., and Pfizer Inc.; leading AIDS charities such as Broadway Cares/Equity Fights AIDS, Crusaid, Deutsche AIDS-Stiftung, and Until There’s A Cure Foundation; other private donors such as the Haas Charitable Trusts; and many generous individuals from around the world.
Imagine a world without AIDS